Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis

Publisher： Karger

E-ISSN： 1423-0100|56|1|37-45

ISSN： 0300-5526

Source： Intervirology, Vol.56, Iss.1, 2012-10, pp. : 37-45

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 79-86

John Wiley & Sons Inc

Access to resources Recommend Favorite

IL28B genotype and treatment outcome in cirrhosis

By  

HEPATOLOGY RESEARCH, Vol. 44, Iss. 9, 2014-09 ,pp. : 983-992

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interferon Reduces the Risk of Hepatocellular Carcinoma in Hepatitis C Virus-Related Chronic Hepatitis/Liver Cirrhosis

By  

Oncology, Vol. 78, Iss. 1, 2010-07 ,pp. : 17-23

Karger

Access to resources Recommend Favorite

Efficacy of telbivudine compared with entecavir in hepatitis B virus‐related cirrhosis: 2 year follow‐up data

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 3, 2015-03 ,pp. : 860-869

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy in Patients with Dose Reduction in Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C

By  

Intervirology, Vol. 51, Iss. 1, 2008-02 ,pp. : 1-6

Karger

Access to resources Recommend Favorite